# HbA1c test, 9/13 (AACC)

Beckman Coulter’s FDA-approved hemoglobin A1c assay (HbA1c) with improved performance is for standard use on the company’s UniCel DxC systems.

The HbA1c reagent was designed and developed to improve accuracy and precision, to continue to meet the latest accuracy grading from the College of American Pathologists and the recommendations of the National Glycohemoglobin Standardization Program and International Federation of Clinical Chemistry.

The assay features ready-to-use liquid reagents for A1c and total hemoglobin; a five-level calibrator set; 30-day onboard reagent stability; seven-day calibration stability; no crossreactivity with HbA1a, HbA1b, acetylated hemoglobin, carbamylated hemoglobin, and glycated albumin; and no significant interference from hemoglobin variants HbS, HbC, HbD, HbE, and HbF.

HbA1c, when used in conjunction with Beckman Coulter’s UniCel DxC system and Synchron/AU hemolyzing reagent, is intended for the quantitative determination of hemoglobin A1c concentration in human whole blood.

***Beckman Coulter***, 800-742-2345